Literature DB >> 28947209

Expression of AR, 5αR1 and 5αR2 in bladder urothelial carcinoma and relationship to clinicopathological factors.

Shuko Hata1, Kazue Ise1, Abdullah Azmahani2, Sachiko Konosu-Fukaya1, Keely May McNamara3, Fumiyoshi Fujishima3, Keiji Shimada4, Koji Mitsuzuka5, Yoichi Arai5, Hironobu Sasano3, Yasuhiro Nakamura6.   

Abstract

AIMS: Bladder urothelial carcinoma is increasing in incidence with age and its prognosis could become worse when accompanied with metastasis. Effective treatment of these advanced patients is required and it becomes important to understand its underlying biology of this neoplasm, especially with regard to its biological pathways. A potential proposed pathway is androgen receptor (AR)-mediated intracellular signaling but the details have remained relatively unexplored. MAIN
METHODS: The expression of AR, 5α-reductase type1 (5αR1) and 5α-reductase type2 (5αR2) were examined in the bladder cancer cell line T24 and surgical pathology specimens. We also evaluated the status of androgen related cell proliferation and migration using the potent, non-aromatizable androgen agonist 5α-dihydrotestosterone (DHT). KEY
FINDINGS: DHT treatment significantly increased AR mRNA expression level, but not those of 5αR1 and 5αR2 in T24 cells. DHT also suppressed cellular migration with weaker and opposite effects on cell proliferation. A significant inverse correlation was detected between pT stage and AR, 5αR1 and 5αR2 immunoreactivity. SIGNIFICANCE: Inverse correlations detected between tumor grade and AR/androgen metabolizing enzyme also suggested that the loss of AR and androgen-producing enzymes could be associated with tumor progression. Effects of DHT on cells also suggest that androgens may regulate cellular behavior.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AR; Bladder urothelial carcinoma; Steroid metabolism

Mesh:

Substances:

Year:  2017        PMID: 28947209     DOI: 10.1016/j.lfs.2017.09.029

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  5 in total

1.  BAYESIAN VARIABLE SELECTION FOR SURVIVAL DATA USING INVERSE MOMENT PRIORS.

Authors:  Amir Nikooienejad; Wenyi Wang; Valen E Johnson
Journal:  Ann Appl Stat       Date:  2020-06-29       Impact factor: 2.083

2.  Expression and clinicopathological significance of glucocorticoid receptor, SGK1, and NDRG1 in hormone-naïve prostate carcinoma.

Authors:  Shuko Hata; Hiroki Shimada; Naomi Sato; Mayu Koshiishi; Kazue Ise; Tomoaki Ogata; Shinichi Yamashita; Akihiro Ito; Hironobu Sasano; Yasuhiro Nakamura
Journal:  Med Mol Morphol       Date:  2022-07-21       Impact factor: 2.070

3.  A Mechanism by which Ergosterol Inhibits the Promotion of Bladder Carcinogenesis in Rats.

Authors:  Nobutomo Ikarashi; Motohiro Hoshino; Tetsuya Ono; Takahiro Toda; Yasuharu Yazawa; Kiyoshi Sugiyama
Journal:  Biomedicines       Date:  2020-06-27

Review 4.  The Role of Androgens and Androgen Receptor in Human Bladder Cancer.

Authors:  Elizabeth Martínez-Rojo; Laura Cristina Berumen; Guadalupe García-Alcocer; Jesica Escobar-Cabrera
Journal:  Biomolecules       Date:  2021-04-18

5.  5α-reductase inhibitors impact prognosis of urothelial carcinoma.

Authors:  Chien-Sheng Wang; Ching-Chia Li; Yung-Shun Juan; Wen-Jeng Wu; Hsiang-Ying Lee
Journal:  BMC Cancer       Date:  2020-09-11       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.